| Literature DB >> 30480224 |
Maya Higuma1, Nobuo Sanjo1, Hiroshi Mitoma2, Mitsuru Yoneyama3, Takanori Yokota1.
Abstract
Background: Gait impairment in patients with Alzheimer's disease (AD) and its relationship with cognitive function has been described, but reports of gait analysis in AD in daily living are limited. Objective: To investigate whether gait pattern of patients with AD in daily living is associated with cognitive function.Entities:
Keywords: Alzheimer’s disease; attention; daily living; gait cycle; portable gait rhythmogram
Year: 2017 PMID: 30480224 PMCID: PMC6159725 DOI: 10.3233/ADR-170001
Source DB: PubMed Journal: J Alzheimers Dis Rep ISSN: 2542-4823
Clinical features and cognitive characteristics of patients with AD and healthy controls (HC)
| Variable | AD ( | HC ( | |
| Age, years | 76.9±4.8 | 74.6±4.4 | 0.209 |
| Gender, male:female | 11:13 | 3:6 | 0.698 |
| Education, years | 13.5±3.3 | 14.2±2.1 | 0.38 |
| Anti-dementia drug usagea | 14/24 (58.3%) | – | – |
| History of fall (past 1 year) | 5/17 (29.4%) | 2/4 (40%) | 1 |
| MMSE score | 22.5±3.0 | 28.8±1.2 | <0.001 |
| Raw index score of WMS-R | |||
| Verbal memory (0–97) | 21.5±11.3 | 69.7±14.5 | <0.001 |
| Visual memory (0–69) | 34.5±9.7 | 58.7±2.8 | <0.001 |
| Attention/concentration (0–88) | 53.3±7.4 | 69.2±7.9 | <0.001 |
| Delayed recall (0–106) | 14.2±14.8 | 76.3±9.0 | <0.001 |
MMSE, Mini-Mental State Examination; WMS-R, Wechsler Memory Scale-Revised. The range of raw index scores is shown in parentheses. aAcetylcholine esterase inhibitor or NMDA receptor antagonist (memantine).
Fig.1Boxplots illustrating the comparison of gait cycle (a) and gait acceleration (b) among patients with Alzheimer disease (AD) and healthy controls (HC). The horizontal line inside the box indicates the median, and the length of the box is the interquartile range (IQR). The extremes of the whiskers contain the data within 1.5 IQR from the upper or lower quartile. The open circles indicate an outlier.
Fig.2(a) Scatter plots indicating the relationship between attention/concentration and gait cycle in patients with AD and healthy controls. Gait cycle and attention/concentration was moderately correlated in patients with AD, but not correlated in HC (p = 0.101). The regression lines for AD (black line) and HC (gray line) are shown. (b) Boxplots showing a comparison of gait cycle between AD-high-att, AD-low-att, and HC. The parameters of these plots are the same as in Fig. 1.
Correlation between gait parameters and cognitive measures
| Gait parameters | ||
| Gait cycle | Gait acceleration | |
| MMSE | –0.147 (0.493) | –0.289 (0.171) |
| WMS-R | ||
| Visual memory | –0.253 (0.232) | –0.040 (0.852) |
| Visual memory | –0.137 (0.524) | –0.058 (0.789) |
| Attention/concentration | 0.578 (0.003) | –0.347 (0.097) |
| Delayed recall | –0.056 (0.794) | –0.042 (0.844) |
The Spearman correlation coefficients (r), with associated p-value in parentheses, are shown.
Differences in gait cycle and attention score in patients with AD
| Variable | AD-high-att | AD-low-att | HC | ||||
| ( | ( | ( | overall | AD-high versus | AD-high | AD-low | |
| AD-low | versus HC | versus HC | |||||
| Age, years | 78.8±3.2 | 76.2±5.1 | 74.6±4.5 | 0.177 | – | – | – |
| Anti-dementia drug usage | 4/5 (80%) | 9/18 (50%) | – | – | 0.341b | – | – |
| MMSE | 23.2±23.2 | 22.3±2.8 | 28.8±1.2 | <0.001 | 0.523 | <0.001 | <0.001 |
| Attention/concentration | 63.7±4.8 | 49.9±4.1 | 69.2±7.9 | <0.001 | <0.001 | 0.425 | <0.001 |
| Gait cycle (s) | 1.34±0.09 | 1.21±0.05 | 1.2±0.06 | 0.013 | 0.011 | 0.048 | 0.994 |
| Gait acceleration (m/s2) | 1.79±0.16 | 1.93±0.29 | 1.99±0.31 | 0.374 | – | – | – |
aComparison among three groups were conducted by Kruskal-Wallis ANOVA by ranks with Steel-Dwass post-hoc analysis. bComparison between two groups was conducted by Fisher’s exact test.